MIT Team Builds Shoebox-Sized Glucose Monitor, Targets 2029 Market Debut
Updated
Updated · Gizmodo · May 28
MIT Team Builds Shoebox-Sized Glucose Monitor, Targets 2029 Market Debut
1 articles · Updated · Gizmodo · May 28
Summary
A December 2025 MIT study showed a shoebox-sized noninvasive glucose monitor worked against traditional glucose monitors, marking a major step beyond earlier desktop-printer-sized systems.
The device uses Raman spectroscopy to read glucose through skin, but the signal is extraordinarily faint—about 1 Raman photon for every 1 million photons sent in.
MIT’s 2020 breakthrough came from filtering tissue noise by changing the angle of near-infrared illumination and signal collection, helping isolate glucose’s molecular signature.
Miniaturization remains the main hurdle because smaller optics collect less light, while glucose readings still must match finger-prick accuracy closely enough for clinical use.
Apollon, a startup tied to the project, is now handling development toward clinical trials and FDA clearance, with a commercial launch targeted for 2029 or 2030.
Can MIT's laser technology succeed where Google's smart lens failed, finally delivering needle-free glucose monitoring?
Will real-time glucose data for all create healthier lives or just a new wave of digital health anxiety?
From Shoebox to Smartwatch: MIT’s Noninvasive Glucose Monitoring Breakthrough and 2029 Market Roadmap
Overview
MIT is leading the development of a noninvasive blood glucose monitor that could transform diabetes care. This innovative device uses Raman spectroscopy, a light-based technique, to measure glucose levels through intact skin without needles or wires. By shining near-infrared light on the skin, the device detects molecular vibrations and infers glucose concentration from the resulting signals. This approach eliminates the need for daily finger pricks, offering a more comfortable and convenient solution for people with diabetes. The technology promises to make glucose monitoring easier, paving the way for better disease management and improved quality of life.